Skip to content
LexBuild

Manufacturer of Controlled Substances; Notice of Application; Patheon Pharmaceuticals, Inc.

---
identifier: "/us/fr/2013-07138"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Manufacturer of Controlled Substances; Notice of Application; Patheon Pharmaceuticals, Inc."
title_number: 0
title_name: "Federal Register"
section_number: "2013-07138"
section_name: "Manufacturer of Controlled Substances; Notice of Application; Patheon Pharmaceuticals, Inc."
positive_law: false
currency: "2013-03-28"
last_updated: "2013-03-28"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Justice Department"
document_number: "2013-07138"
document_type: "notice"
publication_date: "2013-03-28"
agencies:
  - "Justice Department"
  - "Drug Enforcement Administration"
fr_citation: "78 FR 19016"
fr_volume: 78
---

#  Manufacturer of Controlled Substances; Notice of Application; Patheon Pharmaceuticals, Inc.

Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on February 22, 2013, Patheon Pharmaceuticals, Inc., 2110 E. Galbraith Road, Cincinnati, Ohio 45237, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Gamma Hydroxybutyric Acid (2010), a basic class of controlled substance listed in schedule I.

The company plans to manufacture the listed controlled substance for distribution to its customers.

Any other such applicant, and any person who is presently registered with DEA to manufacture such substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than May 28, 2013.

Dated: March 20, 2013.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.